OHSU Knight Cancer Institute
Brian Druker's institute, where imatinib was proven in CML and precision oncology was born; now focused on early detection and functional genomics.
NCI-designated since 1997, the Knight Cancer Institute is led by Brian Druker, whose clinical development of imatinib for BCR-ABL-positive chronic myeloid leukaemia in the late 1990s established targeted therapy as a paradigm. A $1 billion fundraising campaign completed in 2015 funded the Cancer Early Detection Advanced Research (CEDAR) centre and new research buildings on Portland's South Waterfront. Jeffrey Tyner's functional drug screening created the Beat AML programme, Joe Gray's SMMART trials pursue serial multi-omic profiling of individual patients, and Lisa Coussens leads work on myeloid cells in the tumour microenvironment. Charles Blanke chairs SWOG from OHSU.
- CML and targeted therapy
- Early detection (CEDAR)
- Functional genomics (Beat AML)
- SMMART n-of-1 trials
Pages like this
not linked directly; found by shared links- Key paperFirst imatinib trial: a pill that switched off the enzyme driving chronic myeloid leukaemia
Shares BCR::ABL1 (Philadelphia chromosome), Chronic myeloid leukaemia (CML), Imatinib, Novartis.
- ProductBosutinib
Shares BCR::ABL1 (Philadelphia chromosome), Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors.
- PersonBud Romine
Shares BCR::ABL1 (Philadelphia chromosome), Chronic myeloid leukaemia (CML), Imatinib, Small-molecule kinase inhibitors.
- ProductNilotinib
Shares BCR::ABL1 (Philadelphia chromosome), Chronic myeloid leukaemia (CML), Novartis, Small-molecule kinase inhibitors.
- Key paperIRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia
Shares BCR::ABL1 (Philadelphia chromosome), Chronic myeloid leukaemia (CML), Imatinib, Novartis.
- PersonBrian Druker
Shares BCR::ABL1 (Philadelphia chromosome), Chronic myeloid leukaemia (CML), Imatinib, Small-molecule kinase inhibitors.
- ProductAsciminib
Shares BCR::ABL1 (Philadelphia chromosome), Chronic myeloid leukaemia (CML), Novartis, Small-molecule kinase inhibitors.
- PersonJanet Rowley
Shares BCR::ABL1 (Philadelphia chromosome), Chronic myeloid leukaemia (CML), Imatinib, Acute myeloid leukaemia.